Conferences

Corbus Presents Latest Preclinical Data for CRB-601 at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference

05/24/2022

CRB-601 is a highly potent and selective anti-αvβ8 integrin monoclonal antibody designed to block the activation of TGFb in the local tumor microenvironment Additional non-clinical data demonstrates combination benefit across a diverse range of syngeneic models with differential sensitivity to checkpoint inhibition Anti-tumor activity correlates with increases in proliferating CD4+ and CD8+ T-cells as well as the NK…

Read More

Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual Meeting

05/23/2022

Taxanes, such as paclitaxel and docetaxel, cause severe and often permanent chemotherapy-induced hair loss (alopecia) New non-clinical data demonstrate proof of principle that ALRN-6924 can temporarily arrest the cell cycle in human scalp hair follicles and their stem cells ALRN-6924-induced cell cycle arrest protected hair follicles from paclitaxel-induced toxicity and irreversible stem cell damage Aileron’s…

Read More

Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the Association for Research in Vison and Ophthalmology Conference

05/12/2022

Studies in non-human primates demonstrated nearly 100% gene editing knockout of endogenous RHO gene and more than 30% replacement protein levels Treated eyes showed morphological and functional photoreceptor preservation  EDIT-103 advancing towards IND-enabling studies Excerpt from the Press Release: CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome…

Read More

Meet with Christopher Kata and the TrialStat team (booth # 923), during the SCOPE Summit for Clinical Operations Execs, February 7th – 10th, in Orlando, Florida!

01/25/2022

Meet with Christopher Kata, Director of Sales & Marketing February 7th – 10th, 2022 at the SCOPE Summit for Clinical Operations Executives in Orlando, Florida. Christopher and the TrialStat team are exhibiting in booth # 923. Christopher Kata, Director of Sales & Marketing905 [email protected] Event: SCOPE – Summit for Clinical Operations Executives When: February 7th…

Read More

Second Genome Presents Preclinical Data at Crohn’s & Colitis Foundation’s® IBD Innovate Conference for Potential First in Class Mucosal Healing Therapeutic SG-5-00455

11/25/2021

SG-5-00455 delivered directly to the gut via engineered L. lactis system restores barrier function and improves mucosal healing in an ulcerative colitis model Company also participates as new Crohn’s & Colitis Foundation Corporate Circle member to support Foundation’s IBD treatment, awareness and patient engagement initiatives Excerpt from the Press Release: BRISBANE, Calif. – November 18,…

Read More

Wugen Presents New Preclinical Data from Novel Memory Natural Killer (NK) Platform at The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

11/18/2021

— Wugen’s proprietary platform employs a GMP-grade, feeder cell-free manufacturing process to produce commercially scalable, off-the-shelf, non-engineered memory natural killer (NK) cell therapies with enhanced anti-tumor function — — Lead product candidate WU-NK-101 demonstrated potent anti-tumor activity and long-term persistence in vivo — — Data support ongoing clinical development of WU-NK-101 as best-in-class memory NK…

Read More

Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer at Society for Immunotherapy of Cancer (SITC) Annual Meeting

11/17/2021

21.4% Overall Response Rate (ORR) in Heavily Pre-Treated Patients with Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC) Conference Call and Webcast on Saturday, November 13 at 5:30pm ET Excerpt from the Press Release: SAN CARLOS, Calif., and WASHINGTON, Nov. 12, 2021 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel…

Read More

Spirovant Presents Preclinical Data Showing SP-101 Restores CF Transmembrane Conductance Regulator Function at the 2021 North American Cystic Fibrosis Conference

11/10/2021

Excerpt from the Press Release: Philadelphia, PA, November 4, 2021 – Spirovant Sciences, a gene therapy company developing treatments and cures for inherited respiratory diseases including cystic fibrosis (CF), today presented SP-101, an investigational novel recombinant adeno-associated virus (AAV) gene therapy selected for its tropism to human airway epithelia, at the 2021 North American Cystic Fibrosis Conference (NACFC 2021).…

Read More

ReCode Therapeutics Presents Preclinical Data from mRNA-based Cystic Fibrosis Program at 2021 North American Cystic Fibrosis Conference

11/08/2021

– Data show ability to rescue cystic fibrosis transmembrane conductance regulator (CFTR) function using proprietary lipid nanoparticle (LNP) platform to deliver optimized CFTR mRNA as an aerosol to patient-derived human bronchial epithelial cells – Optimized LNP formulation delivered mRNA to therapeutically relevant lung secretory and basal cells Excerpt from the Press Release: MENLO PARK, Calif. & DALLAS–(BUSINESS…

Read More

Biocom California Announces Sixth Annual Life Science Catalyst Award Winners

11/05/2021

Een life science trailblazers under the age of 40 recognized across California Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif. & LOS ANGELES & SAN DIEGO–(BUSINESS WIRE)–Biocom California, the association representing the California life science industry, today announced the winners of its sixth annual Life Science Catalyst Awards. The awards celebrate the accomplished and up-and-coming…

Read More